Effect of Cardiac Protection with Intralipid after Insult during Off-Pump Coronary Artery Bypass Surgery

Effect of Post-conditioning with Intralipid in Patients Undergoing Off - Pump Coronary Artery Bypass Surgery - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/11/060068

Enrollment

Registered

2023-11-21

Start date

Unknown

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I251- Atherosclerotic heart disease of native coronary artery Health Condition 2: I25- Chronic ischemic heart disease Health Condition 3: I20-I25- Ischemic heart diseases Health Condition 4: I24- Other acute ischemic heart diseases

Interventions

Intervention1: Intralipid Infusion: Infusion of 20% Intralipid 2ml/kg immediately after completion of revascularisation over a period of 30 minutes Control Intervention1: Control: Infusion of normal s

Eligibility

Inclusion criteria

Inclusion criteria: Patients posted for elective Off Pump Coronary Artery Bypass Surgery (OPCAB) with left ventricular ejection fraction (LVEF) > 40 %

Exclusion criteria

Exclusion criteria: Combined valve and coronary surgery, onpump CABG, redo cardiac surgery, hyperlipidaemia, significant hepatic or renal dysfunction, uncontrolled hypertension, any disorder with immunological dysfunction (eg, malignancy or positive serological test for the HIV) in the last 6 months, preoperative treatment with nicorandil (an ATP-sensitive potassium channel opener), sulfonylurea (an ATP- sensitive potassium channel blocker)

Design outcomes

Primary

Measure	Time frame
To evaluate the cardioprotective role of Intralipid (IL) by assessing Troponin I postoperatively 6th hourly, 24th hourly, 48th hourly and 72th hourly.Timepoint: To evaluate the cardioprotective role of Intralipid (IL) by assessing Troponin I postoperatively 6th hourly, 24th hourly, 48th hourly and 72th hourly.	—

Secondary

Measure	Time frame
LVEFTimepoint: at time of discharge;to estimate the clinical effect of inotropic useTimepoint: Intraoperatively , POD-1 and POD-2;To find out the effect of intralipid on the serum levels of blood lipids, serum creatinine and total bilirubin.Timepoint: preoperatively, postoperatively POD1 and POD2;to find out the effector intralipid on the ventilatory hours and length of ICU stay post-operativelyTimepoint: Postoperative period;to find out the hemodynamic effect of intralipid on systemic circulationTimepoint: intraoperativelyafter initiating intralipid infusion at 0, 1 min, 5 min, 10 min, 15 min, 20 min, 25 min, 30 min and post-operatively after shifting;To find out the outcome on the complications occurring during hospitalisation including arrhythmias, stroke, infection, respiratory failure, hepatic or renal failure, reoperation and mortality will be notedTimepoint: intra-operative period and post-operative period	—

Measure

Time frame

LVEFTimepoint: at time of discharge;to estimate the clinical effect of inotropic useTimepoint: Intraoperatively , POD-1 and POD-2;To find out the effect of intralipid on the serum levels of blood lipids, serum creatinine and total bilirubin.Timepoint: preoperatively, postoperatively POD1 and POD2;to find out the effector intralipid on the ventilatory hours and length of ICU stay post-operativelyTimepoint: Postoperative period;to find out the hemodynamic effect of intralipid on systemic circulationTimepoint: intraoperativelyafter initiating intralipid infusion at 0, 1 min, 5 min, 10 min, 15 min, 20 min, 25 min, 30 min and post-operatively after shifting;To find out the outcome on the complications occurring during hospitalisation including arrhythmias, stroke, infection, respiratory failure, hepatic or renal failure, reoperation and mortality will be notedTimepoint: intra-operative period and post-operative period

—

Countries

India

Contacts

Public ContactDr Gegal Pruthi

All India Institute of Medical Sciences, Bathinda

drpkc12@gmail.com8558038098

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026